Stada Arz group makes further investment in Serbia

Germany-based generic drugmaker Stada Arzneimittel’s (SAZ: Xetra) Serbian subsidiary Hemofarm recently celebrated the opening of a state-of-the-art production and filling facility for ampoules in Vršac.

Stada has thus invested a total of around 150 million euros ($169 million) in Serbia since the integration of the largest Serbian health company into the Group in 2006. The value of the new plant amounts to 4.37 million euros.

"We are very proud of this new production facility with its equipment and technology of the highest international standard. We have thus once again strengthened one of our most important locations and our international competitiveness," says Hartmut Retzlaff, chairman of the executive board at Stada. The opening of the new plant took place on the 55th anniversary of Hemofarm in the presence of the Serbian Prime Minister Aleksandar Vučić.